Your session is about to expire
Jardiance vs Tradjenta
Introduction
For patients with Type 2 diabetes, managing blood sugar levels is critical to prevent serious complications. Jardiance and Tradjenta are two such drugs that help control high blood sugar levels associated with type 2 diabetes. Both medicines work in unique ways but aim at the same goal of stabilizing glucose levels in your body.
Jardiance (Empagliflozin) works by helping kidneys get rid of glucose from your bloodstream whereas, Tradjenta (Linagliptin) operates differently by increasing the amounts of certain natural substances that lower blood sugar when it gets too high.
Both medications should be used alongside a proper diet and exercise regimen for maximum efficiency. However, they may have distinct side effects; Jardiance can lead to dehydration or yeast infections while Tradjenta could cause pancreatitis or joint pain. It's essential to consult a healthcare professional before making any changes to your medication plan.
What is Jardiance?
Empagliflozin (the generic name for Jardiance) was introduced as a breakthrough in the class of drugs known as SGLT2 inhibitors. Approved by the FDA in 2014, it is used to control blood sugar levels in people with type 2 diabetes. Jardiance works by promoting the removal of sugar through urine, effectively lowering glucose levels in the bloodstream. It can be prescribed on its own or alongside other diabetes medications depending on individual patient needs.
On the other hand, Linagliptin (the generic name for Tradjenta) belongs to another class of anti-diabetic drugs called DPP-4 inhibitors and received FDA approval a few years earlier than Jardiance, in 2011. Tradjenta works differently from Jardiance by increasing hormones that stimulate insulin production after meals thereby decreasing the amount of glucose made by your body.
Both medicines are designed to manage blood sugar levels but their influence on weight varies; while use of Tradjenta generally leads to weight neutrality, Jardiance often results in mild-to-moderate weight loss due to increased calorie loss via urine output.
What conditions is Jardiance approved to treat?
Jardiance is approved for the treatment of specific conditions related to diabetes:
- Type 2 diabetes Mellitus (T2DM), as an adjunct to diet and exercise, to improve glycemic control in adults
- Reducing the risk of cardiovascular death in adult patients with T2DM and established cardiovascular disease
- Chronic kidney disease at stage 3 or higher, reducing the risk of progression to end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure.
How does Jardiance help with these illnesses?
Jardiance helps to manage type 2 diabetes by reducing the amount of glucose reabsorbed by the kidneys, and increasing its excretion in urine. This is accomplished through its action as a sodium-glucose co-transporter-2 (SGLT2) inhibitor. SGLT2 is a protein in the kidneys that absorbs glucose back into the body from filtered blood. By inhibiting this protein, Jardiance increases glucose elimination and thereby lowers blood sugar levels. Glucose is a simple sugar that serves as an essential source of energy for our bodies, but when present at high levels it can cause damage to organs such as heart, nerves and kidneys - common complications in diabetic patients.
Tradjenta on the other hand works differently; it slows down digestion of food by inhibiting DPP-4 enzymes which prolongs absorption rate of carbohydrates and hence reduces spikes in blood sugar after meals. Both medications have their own advantages and different side effect profiles which should be discussed with your healthcare provider before making any decisions regarding your treatment plan.
What is Tradjenta?
Tradjenta is a brand name for linagliptin, which is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase-4). By inhibiting this enzyme, it increases levels of incretin hormones in the body. These hormones are released after a meal and stimulate insulin synthesis while also reducing glucagon concentration. This results in lower blood glucose levels without causing hypoglycemia (low blood sugar). Linagliptin was first approved by the FDA in 2011. As it does not work by increasing insulin production directly, its side effect profile differs from that of other anti-diabetic medications such as sulfonylureas or meglitinides. Notably, it does not cause weight gain and has a low risk of inducing hypoglycemia - common concerns with many diabetes treatments including Jardiance. The effects on incretin hormone regulation can be beneficial for managing type 2 diabetes mellitus, especially for patients who do not respond well to other classes of anti-diabetic drugs.
What conditions is Tradjenta approved to treat?
Tradjenta is an oral medication that's approved for the treatment of:
- Type 2 diabetes, as a standalone drug or in combination with other drugs
- Improvement of blood sugar control along with diet and exercise.
Remember, it's important to always discuss any concerns regarding your medication with a healthcare professional.
How does Tradjenta help with these illnesses?
Tradjenta, like Jardiance, is a medication that helps to manage blood glucose levels in patients with type 2 diabetes. It works by inhibiting DPP-4, an enzyme that degrades incretin hormones. These hormones play vital roles in the regulation of insulin and glucagon secretion - both crucial for maintaining proper blood sugar balance. By blocking this degradation process, Tradjenta allows higher levels of active incretins to remain in the body which leads to increased insulin release and decreased glucagon production when needed most - after meals. This ultimately reduces high post-meal blood sugar spikes often observed in diabetic patients. While Jardiance operates via a different mechanism—that is, it causes excess glucose to be expelled from the body through urine—Tradjenta focuses on enhancing natural regulatory processes within the body itself rather than eliminating excess glucose externally.
How effective are both Jardiance and Tradjenta?
Both empagliflozin (Jardiance) and linagliptin (Tradjenta) have established histories of success in treating patients with type 2 diabetes, as they were approved by the FDA only a couple of years apart. As they act on different aspects of glucose regulation, they may be prescribed under different circumstances. The effectiveness of Jardiance and Tradjenta in managing blood sugar levels was directly studied in several clinical trials; both drugs exhibited similar efficacy at reducing HbA1c levels - a measure for long term glucose control.
In addition to their primary function, Jardiance has been demonstrated to reduce cardiovascular events such as heart attack or stroke among those with pre-existing heart disease - an effect that is not seen with Tradjenta. Furthermore, some studies suggest that Jardiance can promote modest weight loss and lower blood pressure, which are beneficial side effects considering many individuals with Type 2 Diabetes struggle with obesity and hypertension.
On the other hand, being part of the DPP-4 inhibitor class makes Tradjenta less likely to cause hypoglycemia than certain other anti-diabetic medications. It also does not require dose adjustment in renal impairment unlike many others including SGLT-2 inhibitors like Jardiance.
Although both drugs are generally well-tolerated by most patients without serious adverse reactions, potential side effects include urinary tract infections for Jardiance due to its mechanism involving increased urinary glucose excretion while upper respiratory tract infection has been reported more frequently among users of Tradjenta.
Ultimately it's essential for healthcare professionals along patient’s personal preference play into decision-making when choosing between these two effective treatments for type 2 diabetes management.
At what dose is Jardiance typically prescribed?
Jardiance is typically prescribed at an initial oral dose of 10 mg once daily, which can be increased to a maximum of 25 mg per day if additional glycemic control is needed. It should not be used in patients with severe renal impairment or end-stage renal disease. On the other hand, Tradjenta is usually taken orally at a standard dosage of 5 mg/day regardless of meals. This dosage remains the same for most people and should not exceed this limit under any circumstances. However, for those with kidney problems, your doctor may prescribe a lesser dose.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Tradjenta typically prescribed?
Tradjenta treatment typically begins with a dosage of 5 mg/day. The dosage is taken once daily and does not need to be divided into multiple doses or spaced out over the course of the day, making it convenient for patients. Although there is no practice of increasing the dose as seen in other medications, if a patient sees no response to Tradjenta at 5 mg/day after several weeks, their physician may consider adding another type of diabetes medication rather than increasing the dose. Remember that the management of blood sugar levels is crucial in diabetes care so regular monitoring and adjustments are often necessary based on individual responses.
What are the most common side effects for Jardiance?
Common side effects of Jardiance can include:
- Urinary tract infections
- Yeast infections in females and males
- Thirst due to increased urination
- Changes in cholesterol levels
- Nausea, and occasionally vomiting
- Kidney problems (with symptoms like changes in the amount of urine or color)
On the other hand, Tradjenta can cause some different side effects which include:
- Nasopharyngitis (inflammation of the nose and throat)
- Headache
- Diarrhea
- Hypoglycemia (low blood sugar) if used with drugs that reduce blood sugar.
As always, it's important to consult a healthcare professional for advice tailored to your specific health situation.
Are there any potential serious side effects for Jardiance?
While Jardiance and Tradjenta are both used to manage blood sugar levels in patients with Type 2 diabetes, they may have different side effects. For Jardiance:
- Be attentive for any signs of allergic reactions such as hives, difficult breathing, or swelling in the face or throat
- In rare cases, a severe infection of the genital area (Fournier's gangrene) can occur; watch for fever or tenderness/swelling in the genital region
- It is not common but dehydration symptoms might arise due to nausea/vomiting/diarrhea, sweating excessively or not drinking enough fluids
- Seek immediate medical help if you experience unusual tiredness/weakness along with nausea/vomiting and stomach/abdominal pain as it could be an indication of ketoacidosis
For Tradjenta:
- Watch out for signs of pancreatitis: severe abdominal pain that radiates to your back and accompanied by vomiting
- Unusual skin blisters could indicate bullous pemphigoid; seek immediate medical attention.
It is important to remember that these medications should be taken under proper medical supervision only. Always report any unusual side effects to your healthcare provider immediately.
What are the most common side effects for Tradjenta?
Tradjenta, a common medication for type 2 diabetes, could lead to several side effects. These include:
- Upper respiratory tract infection symptoms such as stuffy or runny nose and sore throat.
- Symptoms of low blood sugar including dizziness, sweating, fast heartbeat and fainting.
- Headache
- Muscle pain
- Sinus discomfort
- Increased urination due to the body's attempt to remove excess glucose through urine.
It is critical that users speak with their healthcare professional if these or other side effects occur after starting Tradjenta.
Are there any potential serious side effects for Tradjenta?
Traditionally, Tradjenta is considered relatively safe for use in managing type 2 diabetes. However, like all medications, it can potentially cause severe reactions in rare instances. Here are some symptoms that may indicate a serious adverse reaction to Tradjenta and should prompt immediate medical attention:
- Signs of an allergic reaction such as hives; difficulty breathing; swelling of your face, lips, tongue or throat.
- Signs of pancreatitis including severe pain in your upper stomach spreading to your back, nausea with or without vomiting, and rapid heart rate.
- Symptoms related to heart failure like shortness of breath (even while lying down), swelling in your legs or feet, rapid weight gain.
- Unusual changes in mood or behavior
- Skin reactions such as blistering or peeling rash -In case you observe any joint pain accompanied by fever and fatigue.
If you encounter any of these symptoms while using Tradjenta for type 2 diabetes management, please consult a healthcare professional immediately.
Contraindications for Jardiance and Tradjenta?
Both Jardiance and Tradjenta, like most other diabetes medications, can cause side effects in some people. You need to monitor your blood sugar levels regularly. If you notice significant changes or experience symptoms of high or low blood sugar such as intense thirst, frequent urination, unexplained weight loss or gain, tingling hands/feet, feeling jittery/weak/shaky/sweaty/dizzy/faint/hungry/blurred vision/headachy/confused/moody - contact your healthcare provider immediately.
Neither Jardiance nor Tradjenta should be taken if you are using insulin therapies or drugs that increase insulin production unless directed by a doctor due to the risk of hypoglycemia (low blood sugar). Make sure to tell your physician about all the medications you are taking as some may interact with these diabetes drugs.
Patients on either drug who have kidney disease should disclose this condition to their doctor since both medicines are not recommended for use in patients with severe renal impairment. Also inform them if there is any history of pancreatitis because DPP-4 inhibitors like Tradjenta have been associated with an increased risk of developing it.
Furthermore, Jardiance has a potential risk for leading to ketoacidosis – a serious condition where the body produces excess blood acids called ketones. Check for signs like trouble breathing, nausea/vomiting/stomach-area pain, confusion/unusual sleepiness/fatigue even if your glucose level isn't very high.
How much do Jardiance and Tradjenta cost?
For the brand name versions of these drugs:
- The price for a 30-day supply of Jardiance (10 mg) averages around $500, which works out to about $16.70/day.
- A monthly supply of Tradjenta (5 mg) is priced at approximately $470, equating to roughly $15.70/day.
Therefore, if you are prescribed the standard dosage for either drug, then brand-name Tradjenta tends to be slightly less expensive on a per-day treatment basis. However, cost should not be your primary consideration in determining which medication is right for you.
Currently there are no generic equivalents available for either Jardiance or Tradjenta so costs remain high:
- Although both medications are available in higher dose forms (25mg for Jardiance and 10mg for Tradjenta), their prices do increase proportionally making them more costly.
Remember that the choice between these two medications should be based on their efficacy and side effect profiles as well as cost considerations. Consult with your healthcare provider before making any decisions about diabetes management.
Popularity of Jardiance and Tradjenta
Empagliflozin, in generic form as well as brand names such as Jardiance, was estimated to have been prescribed to about 4.8 million people in the US in 2020. Empagliflozin accounted for just over 10% of SGLT2 inhibitor prescriptions in the US. These types of drugs work by helping kidneys get rid of glucose from your bloodstream and has been generally increasing in prevalence since its approval by FDA.
Linagliptin, including brand versions such as Tradjenta, was prescribed to approximately 3.1 million people in the USA during the same period. In the US, linagliptin accounts for around 12% of DPP-4 inhibitor prescriptions; these medications help increase levels of insulin after meals and decrease the amount of sugar made by your body. The overall prescription trend for Linagliptin has remained relatively steady over recent years.
Conclusion
Both Jardiance (empagliflozin) and Tradjenta (linagliptin) have proven efficacy in the management of type 2 diabetes mellitus, with numerous clinical trials supporting their use as more effective than placebo treatments. They may be used together under a physician's guidance, but this should be carefully considered as they also interact with each other. Their different mechanisms of action make them suitable for specific patient groups; Jardiance works by inhibiting the sodium-glucose co-transporter 2 (SGLT2), which helps to lower blood glucose levels and additionally provides cardiovascular benefits. Tradjenta acts by inhibiting dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones, thereby reducing blood glucose levels.
Both drugs are available in generic form, offering significant cost savings especially for patients who must pay out-of-pocket. The introduction to either drug may require an adjustment period where effects might not be immediately noticeable.
The side effect profiles are somewhat similar between these two drugs with both being generally well-tolerated, but there are differences; Jardiance has been associated with greater weight loss while Tradjenta does not typically cause weight change. As always when starting new medication therapy, particularly for chronic conditions like diabetes mellitus type 2, patients should closely monitor their symptoms and seek medical help if they notice any unexpected or worsening changes.